ZA200709456B - Anti-IL2 antibodies - Google Patents

Anti-IL2 antibodies

Info

Publication number
ZA200709456B
ZA200709456B ZA200709456A ZA200709456A ZA200709456B ZA 200709456 B ZA200709456 B ZA 200709456B ZA 200709456 A ZA200709456 A ZA 200709456A ZA 200709456 A ZA200709456 A ZA 200709456A ZA 200709456 B ZA200709456 B ZA 200709456B
Authority
ZA
South Africa
Prior art keywords
antibodies
Prior art date
Application number
ZA200709456A
Other languages
English (en)
Inventor
Baeuerle Patrick
Lumsden John
Pflanz Stefan
Raum Tobias
Volkland Joerg
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of ZA200709456B publication Critical patent/ZA200709456B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
ZA200709456A 2005-06-01 2007-10-31 Anti-IL2 antibodies ZA200709456B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05011845 2005-06-01

Publications (1)

Publication Number Publication Date
ZA200709456B true ZA200709456B (en) 2008-08-27

Family

ID=37025008

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200709456A ZA200709456B (en) 2005-06-01 2007-10-31 Anti-IL2 antibodies

Country Status (15)

Country Link
US (1) US7964707B2 (es)
EP (1) EP1888644A1 (es)
JP (1) JP5414271B2 (es)
KR (1) KR101340559B1 (es)
CN (1) CN101189265B (es)
AU (1) AU2006254333B2 (es)
BR (1) BRPI0610912A2 (es)
CA (1) CA2609234C (es)
IL (1) IL187316A0 (es)
MX (1) MX2007014565A (es)
NO (1) NO20076568L (es)
NZ (1) NZ563213A (es)
RU (1) RU2425054C2 (es)
WO (1) WO2006128690A1 (es)
ZA (1) ZA200709456B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010225448B2 (en) * 2009-03-16 2013-10-24 Teva Pharmaceuticals Australia Pty Ltd Humanised antibodies with anti-tumour activity
AU2010314798B2 (en) * 2009-11-05 2013-10-24 Teva Pharmaceuticals Australia Pty Ltd Treatment of cancer involving mutated KRAS or BRAF genes
JP6262715B2 (ja) * 2012-04-03 2018-01-17 ノーベルメッド セラピューティクス インコーポレイテッド． ヒト化およびキメラ抗ｃ３因子抗体、ならびにその使用
US10011652B2 (en) 2013-12-12 2018-07-03 Umc Utrecht Holding B.V. Immunoglobulin-like molecules directed against fibronectin-EDA
CN105980556B (zh) * 2013-12-26 2020-10-09 田边三菱制药株式会社 人抗il－33中和单克隆抗体
CN106604932A (zh) * 2014-07-10 2017-04-26 诺华公司 人白细胞介素‑2的免疫刺激单克隆抗体
US10138298B2 (en) 2015-10-23 2018-11-27 The Regents Of The University Of California Anti-IL-2 antibodies and compositions and uses thereof
KR20180100224A (ko) 2016-01-11 2018-09-07 노바르티스 아게 인간 인터루킨-2에 대한 면역-자극 인간화 단일클론 항체, 및 이의 융합 단백질
US11427632B2 (en) 2016-07-06 2022-08-30 Celgene Corporation Antibodies with low immunogenicity and uses thereof
EP3518969A2 (en) 2016-09-28 2019-08-07 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
EP3630825B1 (en) * 2017-05-25 2024-02-14 Institute For Basic Science Anti-human interleukin-2 antibodies and uses thereof
EP3677281A4 (en) 2017-08-31 2021-05-12 Mitsubishi Tanabe Pharma Corporation THERAPEUTIC AGENT CONTAINING AN IL-33 ANTAGONIST TO TREAT ENDOMETRIOSIS
WO2020248938A1 (zh) * 2019-06-10 2020-12-17 山东博安生物技术有限公司 抗cd25抗体及其应用
JP2024512709A (ja) 2021-03-30 2024-03-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト プロテアーゼ活性化ポリペプチド
CN116284380A (zh) * 2021-05-14 2023-06-23 厦门柏慈生物科技有限公司 白细胞介素2结合分子、其衍生物、试剂盒及其生产方法和用途
WO2024068705A1 (en) 2022-09-29 2024-04-04 F. Hoffmann-La Roche Ag Protease-activated polypeptides
CN115850471A (zh) * 2022-10-13 2023-03-28 深圳市百士通科技开发有限公司 一种抗人il-2单克隆抗体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1290031A4 (en) 2000-05-24 2004-09-22 Smithkline Beecham Corp SIALOADHESIN FACTOR ANTIBODIES
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
ES2401136T3 (es) * 2002-11-15 2013-04-17 Genmab A/S Anticuerpos monoclonales humanos contra CD25
EP1653844B1 (en) * 2003-08-13 2012-12-12 Novartis Vaccines and Diagnostics, Inc. Prion-specific peptide reagents

Also Published As

Publication number Publication date
AU2006254333A1 (en) 2006-12-07
US20080317746A1 (en) 2008-12-25
NO20076568L (no) 2008-02-19
BRPI0610912A2 (pt) 2008-12-02
CA2609234A1 (en) 2006-12-07
WO2006128690A1 (en) 2006-12-07
MX2007014565A (es) 2008-02-11
AU2006254333B2 (en) 2011-02-17
CN101189265A (zh) 2008-05-28
RU2007143996A (ru) 2009-07-20
CA2609234C (en) 2014-04-22
US7964707B2 (en) 2011-06-21
KR20080032046A (ko) 2008-04-14
KR101340559B1 (ko) 2013-12-11
JP5414271B2 (ja) 2014-02-12
EP1888644A1 (en) 2008-02-20
JP2008542321A (ja) 2008-11-27
CN101189265B (zh) 2012-07-04
RU2425054C2 (ru) 2011-07-27
NZ563213A (en) 2009-07-31
IL187316A0 (en) 2008-04-13

Similar Documents

Publication Publication Date Title
HK1218126A1 (zh) 抗體
ZA200709456B (en) Anti-IL2 antibodies
IL187106A (en) Sclerostin binds antibody
IL190472A0 (en) Anti-glypican-3 antibody
GB0503546D0 (en) Antibody
IL181575A0 (en) Anti-ox40l antibodies
IL228033A0 (en) Antibodies
GB0517487D0 (en) Antibodies
GB0420466D0 (en) Anti-glucan antibodies
ZA200701952B (en) Anti-OX40L antibodies
EP1780221A4 (en) ANTI-SYNOVIOLIN ANTIBODY
EP1896047A4 (en) ANTI-GFRALPHA3 ANTIBODIES
GB0505489D0 (en) Antibodies
GB0512278D0 (en) Antibodies
GB0505054D0 (en) Antibodies
HK1252408B (zh) 多聚泛蛋白抗體
GB0418415D0 (en) Antibody
GB0420771D0 (en) Antibody
GB0519883D0 (en) Antibodies
GB0500400D0 (en) Antibody
GB0402641D0 (en) Antibodies
GB0402642D0 (en) Antibodies
GB0503190D0 (en) Human antibodies
GB0506945D0 (en) Human antibodies
GB0502201D0 (en) Human antibodies